Background: Hepatitis B surface antigen (HBsAg) and viral load are both hallmarks of hepatitis B virus (HBV) infection and have potential to stratify liver cancer risk. Methods: We carried out a nested case-control study including 211 liver cancer cases and 221 controls who were seropositive for HBsAg within two population-based cohorts in Shanghai. Logistic regression was performed to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). Results: Risk of liver cancer was positively related to increasing levels of HBV-DNA and HBsAg in dose-response manners. Compared with subjects with HBV-DNA < 2000 IU/ ml, the adjusted ORs increased from 2.11 (95%CI: 0.99-4.50) to 10.47 (95%CI: 5.06-21.68) for those with HBV-DNA level at 2000-19 999 to ≥ 20 000 IU/ml. Compared with subjects at a low level of HBsAg (0.05-99 IU/ml), the adjusted ORs increased from 1.82 (95%CI: 0.90-3.68) to 2.21 (95%CI: 1.10-4.43) for those with HBsAg level at 100-999 to ≥ 1000 IU/ml. Compared with subjects with HBV-DNA < 2000 IU/ml and HBsAg < 100 IU/ml, the adjusted ORs were increased from 2.20 (95%CI: 1.07-4.49) for those with HBV-DNA < 2000 and HBsAg ≥ 100 IU/ml to 6.94 (95%CI: 3.39-14.23) for those with HBV-DNA ≥ 2000 IU/ml and HBsAg < 1000 IU/ml, and 16.15 (95%CI: 7.60-34.32) for those with HBV-DNA ≥ 2000 IU/ml and HBsAg ≥ 1000 IU/ml. Conclusion: Elevated levels of HBV-DNA and HBsAg are associated with increased risks of liver cancer. Chronic HBsAg carriers may be suggested to simultaneously lower the viral load to < 2000 IU/ml and HBsAg level to < 100 IU/ml to lower their liver cancer risk.
Introduction
Hepatitis B virus (HBV) infection is a global health problem and roughly 30% of the world's population shows serological evidence of current or past HBV infection. In 2010, about 60-80% of the total liver cancer incidence and half of the mortality was attributed to HBV infection. 1 Thus, the control and treatment of chronic HBV infection is a major and effective approach to lower the morbidity and mortality of liver cancer.
In current clinical practice guidelines, effective suppression of serum HBV-DNA is a marker of efficacy for antiviral therapy. Serum HBV-DNA was indicated to be the major drive of disease progression in patients with chronic hepatitis B (CHB) [2] [3] [4] [5] and was extensively used to monitor and predict hepatocellular carcinoma (HCC) occurrence. [6] [7] [8] [9] The quantification of serum hepatitis B surface antigen (HBsAg) was widely used in the management of CHB patients during recent years. 10, 11 Increasing evidences have suggested that a lower HBsAg level is associated with better clinical outcomes, including a higher likelihood of HBsAg loss, 12 lower risk of hepatitis B e antigen (HBeAg)-negative hepatitis, cirrhosis, and HCC. 13, 14 The combined effect of quantitative HBsAg level and viral load on liver cancer has been investigated in a few hospital-based studies. Studies in Taiwan and Italy suggested that HBsAg quantification level might complement HBV-DNA in the identification of low-risk inactive carriers. 13, 15 Of note, hospital-based studies characterized by high proportion of patients with severe liver disease and worse health condition may expose to selection bias and limit the generalization of the result. To guide the future communitybased surveillance and prediction of liver cancer occurrence, the large-scale population-based prospective studies are still needed to comprehensively evaluate the individual and combined effects of these serum markers of HBV infection on liver cancer risk. In particular, relevant data are still largely lacking in mainland China, where chronic HBV infection accounts for half of the CHB in the world. Thus, we conducted a nested case-control study within two large population-based cohorts in Shanghai to prospectively assess the liver cancer risk by combining the quantitative HBsAg level and viral load.
Materials and methods
Study population. The Shanghai Women's Health Study (SWHS) and the Shanghai Men's Health Study (SMHS) are two large population-based prospective cohort studies currently ongoing in Shanghai, China. The study was approved by the institutional review boards of all collaborating institutions, and all participants provided written informed consent. Details on the cohorts have been described elsewhere. 16, 17 Briefly, a total of 74 941 eligible women aged 40 to 70 years and 61 480 eligible men aged 40 to 74 years were enrolled in the SWHS and SMHS in 1997 to 2000 and 2002 to 2006, respectively. We collected information on demographic characteristics, anthropometric measurements, lifestyle, dietary habits, physical activity, disease history, medication history, and family history of cancer in baseline survey. Of the study participants in the SWHS and SMHS, 56 830 (75.8%) and 46 111 (75.0%) provided a blood sample. The samples were kept in a portable Styrofoam box with ice packs during transportation and processed within 6 hours of collection for long-term storage at À70°C. At the time of sample procurement, a bio-specimen collection form was completed for each participant, which included the information such as the date and time of sample collection and time of last meal.
All cohort members were followed for cancer occurrence through in-person follow-up surveys every 2 to 3 years and annual record linkage with databases of the population-based Shanghai Cancer Registry, Shanghai Vital Statistics Registry, and Shanghai Resident Registry. For the SWHS, the response rates for the first In our previous main liver cancer study (i.e. the parent study of the present one), 18 we included 363 incident liver cancer cases identified during follow-up of the two cohorts through December 2012. We randomly chose 10 control subjects per case among all cohort members, who were individually matched to each case by age (≤ 2 years), sex (male or female), date (≤ 30 days) and time (morning or afternoon) at sample collection, interval since last meal (< 2 hours), and menopausal status (premenopausal or postmenopausal, women only). We tested the baseline plasma samples of all 363 cases and the 3511 matched controls for the presence of HBsAg, of which 432 subjects (211 cases and 221 controls) were seropositive for HBsAg and were finally included in the current study.
Laboratory test. Plasma samples at enrollment were quantified for HBsAg levels using Architect HBsAg QT (Abbott Diagnostic, Shanghai, China) according to the manufacturer's instructions.
Seronegative of HBsAg was defined as a titer of less than 0.05 IU/ml. For subjects with positive HBsAg status (i.e. HBsAg titer ≥ 0.05 IU/ml), the HBV-DNA were further quantified using the Hepatitis B Virus Diagnostic Kit (Real-Time PCR, PerkinElmer, USA) according to the manufacturer's instructions, with a low detection limit of 20 IU/ml. The laboratory personnel were blinded as to the disease status of study subjects whose plasma samples they analyzed.
Statistical analysis. According to the earlier reports, 13, 19 we categorized the HBsAg levels into three groups (0.05-99, 100-999, and ≥ 1000 IU/ml) and categorized the HBV-DNA levels into three groups (< 2000, 2000-19 999 , and ≥ 20 000 IU/ml). Ratio of HBsAg to HBV-DNA was determined to reflect the proportion of subviral particles to virions. Continuous variables were compared with t-test or Mann-Whitney U test as appropriate, and categorical variables were compared with chi-squared test. Spearman's rank correlation coefficient was used to assess the correlation between HBV-DNA and HBsAg levels.
We broke the matched case-control sets of the initial study to maximize the sample size. Unconditional logistic regression was performed to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for liver cancer risk associated with HBV-DNA and HBsAg levels. Covariates were selected as they were known to be associated with liver cancer development. Covariates included in the final model were as follows: education level, family income, family history of liver cancer, HBeAg status, history of chronic hepatitis/other chronic liver diseases, and vegetable intake. Besides the aforementioned covariates, the original matching factors (age, sex, and date and time at sample collection) were also included in the model. Further analyses by additionally adjusting for body mass index, total physical activity, tea consumption, smoking status, alcohol drinking, fruit intake, total energy intake, history of diabetes, and menopausal status (for women) did not change the results materially; thus, we did not enter them into the final model. Besides, no significant interaction effect between HBsAg and HBV-DNA was detected based on the first-degree multiplicative model. Statistical analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC). A two-sided P value of < 0.05 was considered statistically significant.
Results
Baseline characteristics of liver cancer cases and controls were shown in Table 1 . The cases had a median follow-up time of 4.42 years, which was less than the controls (9.53 years). Compared with control subjects, cases had lower family income and education level, less vegetable intake, and were more likely to have reported a family history of liver cancer, a history of chronic liver disease, and seropositive HBeAg. There were no significant differences between cases and controls in body mass index, history of diabetes, total energy intake, fruit intake, physical activity, smoking status, alcohol consumption, and tea drinking.
As shown in Table S1 , HBV-DNA and HBsAg levels were correlated moderately in control subjects (r = 0.63, P < 0.01). The correlation was higher in subjects seropositive for HBeAg Hepatitis B virus and liver cancer risk Y Yang et al. (r = 0.93, P < 0.01), lower in those seronegative for HBeAg (r = 0.58, P < 0.01) and those concurrent with a low HBV-DNA of < 2000 IU/ml (r = 0.56, P < 0.01), and lowest in those seronegative for HBeAg concurrent with a high HBV-DNA of ≥ 2000 IU/ml (r = 0.18, P = 0.27). In addition, the median of HBsAg/HBV-DNA ratio was 0.69 (quartile range = 1.27) in the HBeAg-negative subjects concurrent with HBV-DNA < 2000 IU/ml, which was higher than that in the HBeAgpositive subjects (median = 0.51, quartile range = 0.45) and the HBeAg-negative subjects concurrent with HBV-DNA of ≥ 2000 IU/ml (median = 0.57, quartile range = 0.24) ( Table S2) .
Risk of liver cancer was positively related to increasing levels of HBV-DNA (P trend < 0.01) and HBsAg (P trend = 0.03) in doseresponse manners (Table 2 Subgroup results for different HBsAg cutoff levels on liver cancer risk stratified by HBV-DNA were shown in Tables 3 and 4 . In lowly viremic subjects (HBV-DNA < 2000 IU/ml), subjects with HBsAg level ≥ 100 IU/ml may be at an increased risk of liver cancer (OR = 1.98, 95%CI: 0.96-4.11) compared with those with HBsAg level < 100 IU/ml. The risk was comparable for subjects with HBsAg level < 1000 IU/ml and ≥ 1000 IU/ml (OR = 1.05, 95%CI: 0.42-2.59). In highly viremic subjects (HBV-DNA ≥ 2000 IU/ml), the risk was higher for subjects with HBsAg level ≥ 100 IU/ml than those with HBsAg level < 100 IU/ml (OR = 3.72, 95%CI: 1.17-11.82). Moreover, a higher risk was also observed for subjects with HBsAg level ≥ 1000 IU/ml than those with HBsAg level < 1000 IU/ml (OR = 2.60, 95%CI: 1.11-6.05).
The combined effects of HBV-DNA and HBsAg levels on liver cancer risk were shown in Table 5 . Compared with subjects with minimal risk of liver cancer (HBV-DNA < 2000 IU/ml and HBsAg level < 100 IU/ml), the adjusted ORs were increased from 2.20 (95%CI: 1.07-4.49) for those with HBV-DNA < 2000 IU/ml and HBsAg level ≥ 100 IU/ml to 6.94 (95%CI: 3.39-14.23) for those HBV-DNA ≥ 2000 IU/ml and HBsAg level < 1000 IU/ml, and 16.15 (95%CI: 7.60-34.32) for those with HBV-DNA ≥ 2000 IU/ml and HBsAg level ≥ 1000 IU/ml. 
Discussion
It was the first prospective study to comprehensively evaluate the individual and combined effects of HBV-DNA and quantitative HBsAg levels on liver cancer risk in urban Chinese residents. Using data from two large population-based prospective cohorts in urban Shanghai, we demonstrated that the elevated levels of HBV-DNA and HBsAg were associated with higher risk of developing liver cancer in dose-response manners. The risk started to increase significantly at an HBV-DNA level of 2000 IU/ml and an HBsAg level of 1000 IU/ml. But in lowly viremic subjects (HBV-DNA < 2000 IU/ml), HBsAg > 100 IU/ml was observed to be associated with liver cancer risk. Compared with individuals with HBV-DNA < 2000 IU/ml and HBsAg levels < 100 IU/ml, those with HBV-DNA ≥ 2000 IU/ml and HBsAg level ≥ 1000 were at the high risk of developing liver cancer. We observed a positive correlation between HBV-DNA and HBsAg levels. Previous studies indicated that the correlation changed during the natural history of HBV infection, higher at HBeAg-positive phase and lower at HBeAg-negative phase and the lowly replicative phase, which was consistent with our findings.
20,21 Furthermore, we observed the highest HBsAg/HBV-DNA ratio in HBeAg-negative subjects with HBV-DNA < 2000 IU/ml. Previous studies indicated that the ratio was significantly higher in the low-replicative phase, which was characterized by HBeAg negativity, HBV-DNA < 2000 IU/ml, and normal serum alanine aminotransferase, compared with immune-tolerant, immune-clearance, and HBeAg-negative phases, respectively. 20, 21 These data indicated that the HBV-DNA may be decreased more significantly than HBsAg from the phases of immune-tolerant to immune-clearance. Thus, it was hypothesized that immune control over viral replication may be the first step of immune clearance. Moreover, the discrepancy between HBV-DNA and HBsAg level at the HBeAg-negative phase and lowly replicative phase might be caused by accumulation of integrated viral envelope sequences in infected hepatocytes. During the lowly replicative phase, serum HBsAg levels may mainly derive from the integrated form of HBV-DNA rather than the episomal form and therefore decrease discordantly with serum HBV-DNA. 13 Of note, lowly viremic patients who have high HBsAg level might harbor more hepatocytes with HBV integration than those who have low HBsAg level. 13 The integrated viral sequences may lead to an increased genomic instability, which may play an important role in hepatocarcinogenesis. 13 It has been extensively reported that HBV-DNA was the main drive to HCC development. One of the largest community-based cohort studies in Taiwan (the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus cohort) found that increasing levels of HBV-DNA at study entry was associated with a stepwise increase in HCC risk.
2 High HBV-DNA that started at 10 000 copies/ml was significantly associated with an increased risk of HCC, 2 which was consistent with Recently, HBV-DNA has been incorporated into several risk prediction models to predict HBV-related HCC occurrence, with promising results. 6, 8, 9, 22 In the parent study of the present one, we observed a strong positive dose-response relationship between HBsAg levels and liver cancer risk in a general healthy population. 18 Compared with HBsAg-negative subjects, the corresponding ORs increased from 7.27 to 7.16, 34.30, and 47.33 in men and 1.37 to 3.81, 7.36, and 16.86 in women, with HBsAg level increased from 0.05-9 IU/ml to 10-99 IU/ml, 100-999 IU/ml, and ≥ 1000 IU/ml. 18 Here, after further adjusting for HBV-DNA, such dose-response risk remained significant in HBsAg carriers. HBV-DNA and HBsAg were independent risk factors of HBV-related HCC, which suggested that infectious virions and noninfectious HBsAg particles may have their own unique mechanism of inducing hepatocarcinogenesis. Integration of the new biomarker, quantitative serum HBsAg levels into the risk prediction models may increase the predictability for HCC.
For highly viremic subjects (HBV-DNA ≥ 2000 IU/ml), HBsAg ≥ 100 or ≥ 1000 IU/ml were both identified to be associated with increased risk of liver cancer. Of note, for lowly viremic subjects (HBV-DNA < 2000 IU/ml) who has reported to be at similar risk of liver cancer in earlier reports, 2, 4 HBsAg ≥ 100 IU/ml may be associated with increased risk of liver cancer. These data suggested that HBsAg level might complement HBV-DNA in predicting HCC risk. Another cohort study in Taiwan (the ERADICATE-B [Elucidation of Risk Factors for Disease Control or Advancement in Taiwanese Hepatitis B Carriers] study) also reported that high levels of HBsAg increased the risk of HCC in patients with low HBV load. 13 However, an HBsAg level ≥ 1000 rather than ≥ 100 IU/ml was identified as an independent risk factor for HCC development in the ERADICATE-B cohort members with HBV-DNA < 2000 IU/ml. The discrepancy might be partly due to the hospital-based design for the ERADICATE-B study, which may have higher possibility to enroll subjects with severe liver disease condition (more subjects with HBsAg > 1000 IU/ml than < 1000 IU/ml) compared with a population-based study. 13 Because of limited liver cancer cases (< 5 cases) in subjects with HBsAg of 100-999 IU/ml in the ERADICATE-B study, it may be underpowered to detect the risk associated with lower level of HBsAg level. In the present study, a relative conservative value of 100 IU/ml of HBsAg may be a more suitable cut-point to further stratify the lowly viremic HBV carriers (HBV-DNA < 2000 IU/ml). The findings indicated the importance of lowering serum HBsAg levels in those who already have low serum HBV-DNA levels. When this cutoff value is validated in future studies, physicians may be suggested to adopt it as the intermediate treatment goal to stop nucleos(t)ide analogue therapy.
A strength of this study is based on its prospective design. The HBV-DNA and quantitative HBsAg levels were determined in plasma collected before the development of liver cancer, minimizing the possibility that the HBV-DNA and HBsAg levels were affected by the malignant transformation of hepatocytes or clinical treatment for liver cancer. Second, it is the first population-based study among urban residents in mainland China, where HBV infection is highly endemic. This study could provide valuable data for future community-based prediction and surveillance of liver cancer among urban Chinese residents. The present study also has some limitations. Our quantifications of HBV-DNA and HBsAg level used a single plasma sample obtained at study entry; thus, the changes in HBV-DNA and HBsAg levels over time during follow-up could not be assessed. Second, antiviral therapy may decrease the viral load and be associated with reduced risk of liver cancer. Thus, the effect estimate of viral load may be overestimated without adjusting it in the analysis. However, the study population was recruited from communities, not patients in hospital. They were supposed to have better health condition or asymptomatic infection, minimizing the possibility of medical treatments. Third, other potential confounders such as intake of aflatoxinB1, hepatitis C virus, human immunodeficiency virus infection, and serum metabolic markers were not considered in the present study, which may bias the observed associations.
Conclusion
There is a strong positive dose-response relationship between HBV-DNA and HBsAg levels and risk of liver cancer in these population-based cohorts of residents in urban Shanghai. Individuals with HBV-DNA < 2000 IU/ml and HBsAg < 100 IU/ml should be considered as the minimal-risk HBV carriers and HBV-DNA ≥ 2000 IU/ml and HBsAg ≥ 1000 IU/ml as the highrisk persons of developing liver cancer. Clinical therapy of CHB to simultaneously lower serum levels of both HBV-DNA and HBsAg may be suggested to lower the risk of liver cancer, especially for those high-risk persons.
